People who supplement rescue inhalers with a second asthma medication sometimes get little relief at first, but there’s good news: Those who keep trying different options often find a medication that works, according to Rutgers researchers.
The researchers analyzed data from 2,025 patients who used any of six FDA-approved severe asthma treatments known as “biologics” because they contain monoclonal antibodies found in living organisms.
“The practical takeaway here is pretty simple: Patients who aren’t getting good relief from a particular biologic should try others,” said lead author Reynold A. Panettieri Jr., vice chancellor for translational medicine and science director at the Rutgers Institute for Translational Medicine.
Overall, according to findings published in the Annals of Allergy, Asthma & Immunology, these injectable medications provided significant relief. Patients starting biologics during the study period experienced a 58 percent reduction in exacerbations and 89 percent of those who used biologics at any point during the study period continued to do so at the end.
Some 324 patients switched medications at least once during the study period — most commonly because their symptoms worsened on the first medication or because initially strong effects waned over time — and their strategy was rewarded, the researchers found. Switching medications was consistently associated with a reduction in exacerbations.
“The available products aren’t all me-too drugs,” Panettieri said. “They work in a variety of ways, so it makes sense that different medications would work for different people.”
Journal
Annals of Allergy Asthma & Immunology
Method of Research
Observational study
Subject of Research
People
Article Title
Biologic Use and Outcomes Among Adults with Severe Asthma Treated by United States Subspecialists
Article Publication Date
18-Jun-2022
COI Statement
Reynold A. Panettieri, Jr. is on the advisory boards for and received grant support from AstraZeneca, Sanofi, Genentech, Regeneron, and Novartis. Dennis K. Ledford has been a consultant for AstraZeneca and GlaxoSmithKline and received speaker honoraria from ALK, AstraZeneca, Boehringer Ingelheim, Genentech/Roche, GlaxoSmithKline, Novartis, and Sanofi/Regeneron. Bradley Chipps is on the advisory boards, and a consultant and speaker for AstraZeneca, Boehringer Ingelheim, Genentech, Novartis, Regeneron, Sanofi Genzyme. Weily Soong is a consultant for and receives grant support from AstraZeneca, Genentech, GlaxoSmithKline, Avillion, Novartis, Regeneron, Sanofi, Leo, and Teva, and is a speaker for AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi, and Optinose. Njira Lugogo received consulting fees for advisory board participation from Amgen, AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi, and Teva; honoraria for non-speakers bureau presentations from GlaxoSmithKline and Astra Zeneca; and travel support from Astra Zeneca; her institution received research support from Amgen, AstraZeneca, Avillion, Gossamer Bio, Genentech, GlaxoSmithKline, Regeneron, Sanofi, and Teva. Warner W. Carr is a speaker for AstraZeneca, Teva, Boehringer Ingelheim, Regeneron, and Sanofi, and a consultant for AstraZeneca, Teva, Boehringer Ingelheim, Regeneron, Sanofi, Circassia, CSL Behring, Genentech, GlaxoSmithKline, Horizon Pharma, Kaleo, Mylan, Pfizer, Shire, Meda, Baxalta, Novartis, Greer Laboratories, Alcon Laboratories, Valeant Pharmaceuticals, Grifols, Optinose, and Aerocrine. Arjun Mohan has no disclosures. Donna Carstens, Eduardo Genofre, Frank Trudo, and Christopher S. Ambrose are employees and shareholders of AstraZeneca.